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Abstract
Background: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease.
Methods: Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related
quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared between 131 AATD patients (106 with,
25 without augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the COSYCONET COPD
cohort. The medication costs of AT were excluded from all analyses to reveal differences associated with morbidity
profiles. The association of AATD (with/without AT) with costs or HRQL was examined using generalized linear
regression modelling (GLM) adjusting for age, sex, GOLD grade, BMI, smoking status, education and comorbidities.
Results: Adjusted mean direct annual costs were €6,099 in AATD patients without AT, €7,117 in AATD patients with AT
(excluding costs for AT), and €7,460 in COPD patients without AATD. AATD with AT was significantly associated with
higher outpatient (+273%) but lower inpatient (−35%) and medication costs (−10%, disregarding AT) compared with
COPD patients without AATD. There were no significant differences between groups regarding indirect costs and HRQL.
Conclusion: Apart from AT costs, AATD patients tended to have lower, though not significant, overall costs and similar
HRQL compared to COPD patients without AATD. AT was not associated with lower costs or higher HRQL.
Trial registration: NCT01245933
Keywords: COPD, Alpha-1-Antitrypsin Deficiency, Direct costs, Indirect costs, Health-related quality of life,
Augmentation therapy
Background
Alpha-1-antitrypsin (AAT) is an anti-protease that protects
tissues – mainly lung parenchyma – from damage by en-
zymes released from inflammatory cells. Thus a deficiency
of AAT can lead to uninhibited lung parenchymal destruc-
tion and the development of chronic obstructive pulmonary
disease (COPD), particularly lung emphysema [1]. There
are about 100 different genetic mutations leading to dys-
function of AAT or Alpha-1-antitrypsin deficiency (AATD)
[2] which is also associated with liver cirrhosis [3] and over-
expression of pro-apoptotic pathways [4].
AATD is a very rare but also highly underdiagnosed dis-
ease [5, 6]. The prevalence of deficiency related alleles
(PI*ZZ and PI*SZ) in the world population is estimated to
be 0.1% for the PI*ZZ and 0.7% for the PI*SZ genotype
[7]. However, assessment of the true prevalence is difficult,
as there are no population-based, large-scale screening
studies [1], due to the difficulties of conducting
population-based studies, poor awareness of the disease,
perceived lack of treatment efficacy, and complexity of
testing algorithms [8, 9].
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COPD patients with underlying AATD differ from
COPD patients without this deficiency e.g. with regard to
smoking history, comorbidities and exercise-related desat-
uration in arterial blood [10, 11]. However, standard
COPD therapy is recommended for AATD patients [12].
Comorbidities, which have been identified as a major
driver of excess costs as well as of loss in health-realted
quality of life (HRQL) in COPD patients [13, 14], may dif-
fer between patients with and without AATD.
Therefore, the aim of this cross-sectional analysis was
to compare the annual direct and indirect costs as well
as generic and disease-specific HRQL between COPD
patients with and without AATD. To our knowledge,
this has not yet been done before in a large-scale study.
To identify costs related to (co-)morbidity profiles in
AATD compared to non-AATD patients, the tremen-
dous cost bias from alpha-1-proteinase inhibitor aug-
mentation therapy (AT) was circumvented by excluding
these costs from the analysis. As there is an ongoing
controversy about the efficacy of AT therapy [1, 15], we
also examined differences regarding (non-AT) direct and
indirect costs and HRQL between augmented and non-
augmented AATD patients.
Methods
Data and study design
Data was obtained from the baseline examination of the
German multicentre COPD cohort COSYCONET
(German COPD and Systemic Consequences – Comorbidi-
ties Network). The study included 2,741 subjects with a
clinical diagnosis of COPD. Recruitment took place in 31
study centres between September 2010 and December
2013. Participants had to be ≥40 years of age and stable.
Detailed information on recruitment and exclusion criteria
can be found in Karch et al. [16]. COPD was defined ac-
cording to the GOLD criteria after performing standardized
post-bronchodilator spirometry [17]. For GOLD staging,
reference values according to the Global Lung Initiative
(GLI) were used [18]. 450 subjects with a Tiffeneau index
above 70% at baseline examination were excluded from this
analysis (Fig. 1).
AATD patients were identified by using self-reports on
AATD and its genotype, AT from the medication list and
the measured AAT serum levels. Participants with the het-
erozygous genotype PiMZ were classified as COPD pa-
tients without AATD. If a person answered that they did
not know his or her genotype and was not receiving AT,
Fig. 1 Patient flow diagram
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an AAT serum level cut-off-point of <50 mg/dl was se-
lected to distinguish COPD patients with and without
AATD. With n = 131 patients (6.0%), including 106 pa-
tients with AT and 25 without AT, AATD was overrepre-
sented in COSYCONET (Fig. 1).
Healthcare utilisation, work absenteeism and calculation
of costs
Healthcare utilisation was assessed using standardised
questionnaires and interviews. The calculation of costs has
been described previously [14]. In brief, outpatient phys-
ician visits (last 3 months, subdivided by 13 specialists), and
physiotherapist visits, rehabilitation and days spent in hos-
pital (past 12 months) were considered for the calculation
of direct healthcare costs. These quantities were multiplied
by the German unit costs (Additional file 1) of the year
2012 [19]. Furthermore, currently used prescribed pharma-
ceuticals were considered. Utilization of pharmaceuticals
was estimated based on patients’ information on the drug
code, defined daily doses [20] and German pharmacy retail
prices of the year 2012 [21]. For the calculation of costs per
year all costs were extrapolated to 12 months. In case of
augmented AATD patients, the estimated mean annual
costs of AT, €72,255 [21], were subtracted from the medica-
tion costs. Indirect costs as a consequence of production
losses [22] included the temporary inability to work and
premature retirement for participants aged < 65 years. For
cost calculations the human capital approach was applied
that accounts full labour costs for all sick days (€177 per
missed day in 2012) [22]. Premature retirement (<65 years)
was valued with mean annual labour costs of €37,126 per
year [23]. As there is an ongoing discussion about the ap-
propriate valuation of indirect costs [22], the friction cost
approach was additionally applied. This means, that missed
working days were calculated at only €142 and only for the
first 50 days of work absenteeism, and costs for premature
retirement were omitted [24].
Health-related quality of life
Participants completed the Saint-George’s-Respiratory-
Questionnaire (SGRQ) [25] and the COPD Assessment
Test (CAT) [26]. The scoring of the SGRQ ranges from 0
to 100 whereas CAT ranges from 0 to 40 with higher
scores indicating worse HRQL [25, 26]. The generic
EuroQol 5 dimensions (EQ-5D-3 L) questionnaire includ-
ing Visual Analogue Scale (VAS) was used in addition as
an established German EQ-5D-3 L utility tariff [27]. This
has been demonstrated as suitable for cost-utility analyses
[28]. In both parts of the EQ-5D-3 L, higher values are as-
sociated with a better HRQL.
Comorbidities
Participants were asked: “Has a physician ever diagnosed
you with one of the following diseases?”. Thereby
information on 33 pre-defined comorbidities was
assessed. Comorbidities were added up to a comorbidity
count. Such a count has been shown to perform well in
quantifying comorbidity in COPD patients [29].
Statistical analysis
For comparing characteristics between AATD patients
and COPD control subjects, or between the two sub-
groups of AATD patients, t-tests for continuous, Chi2-
tests for categorical variables, and Wilcoxon signed-rank
tests for ordinal variables were applied.
The association of AATD and AT with direct and
indirect costs was examined via generalised linear re-
gression modelling (GLM). The covariates GOLD
grade 1–4, age, sex, school education, smoking status,
BMI and comorbidity count were added to the model.
As cost data was highly right-skewed, which means
that costs only assume values ≥0 and more individ-
uals have costs below the mean than above, a gamma
model with log-link was assumed. In the case of in-
direct costs only participants aged younger than
65 years were included. Participants with zero-costs
were assigned €1 for regression modeling. Resulting
cost estimates can be directly interpreted as factors.
Adjusted means in direct and indirect costs were esti-
mated as recycled predictions from 1000 bootstrap
replications [30]. GLM with normal distribution was
performed for HRQL scores. Therefore, estimates for
HRQL represent additional units on the HRQL scale.
Statistical analyses were performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA, version 9.3).
For significance testing, a p-value of 0.05 or less was
required. Graphics were edited in R [31] using the
package ggplot2 [32].
Sensitivity analysis
To consider potential residual confounding due to the
categorization of lung function in GOLD grades 1 to 4,
GLM was also performed using the exact predicted percent-
age of Forced Expiratory Volume in 1 second (FEV1 %pred.)
instead of GOLD grades [18].
Ethics statement
The COSYCONET study was approved by the Ethics
Committees of the local study centres. All participants
gave their written informed consent.
Results
Characteristics of the study population
Data of 2049 COPD patients without AATD and 131
with AATD (106 with AT and 25 without AT) were
included in the analysis. Their characteristics are
given in Table 1.
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AATD patients were significantly younger (60.3 vs.
65.4 years, p < 0.001) and in higher GOLD grades than the
COPD patients without AATD (p = 0.01), but showed a
lower number of comorbidities (3.1 vs. 3.9, p < 0.001). Fur-
thermore, AATD patients had a higher proportion of
never-smokers (23.7% vs. 5.4%, p < 0.001) and a lower BMI
(24.7 vs. 26.8 kg/m2, p < 0.001). Comparing AATD patients
receiving AT with AATD patients not receiving AT, signifi-
cant differences regarding the distributions of GOLD
grades and gender were found (Table 1).
Unadjusted healthcare utilisation, work absence and
retirement
AATD patients, compared to COPD patients without
AATD, had about twice as many outpatient visits, a
lower percentage of hospitalizations (24% vs. 39%), a
shorter duration of stay at inpatient services, and a lower
number of prescribed medication (excluding AT)
(Table 2). Also, AATD patients had less sick days and a
lower proportion of premature retirement than COPD
patients without AATD.
Table 1 Characteristics of the study population
Subgroups p-value
A B B1 B2 A vs. B B1 vs. B2
N 2049 131 106 25
Age (years) 65.4 (8.2) 60.3 (10.0) 59.6 (9.9) 63.1 (10.2) <.001a .12a
% Age < 45 years 1.0 3.8 3.8 4.0 <.001b .63 b
% Age 45–55 years 9.1 29.0 30.19 24.0
% Age 56–65 years 33.6 29.8 31.1 24.0
% Age 66–75 years 44.1 31.3 30.2 36.0
% Age > 75 years 12.1 6.1 4.72 12.0
Gender
% Males 61.1 56.5 62.3 32.0 .30b .01b
COPD GOLD Grade .01b <.001b
% Grade 1 (FEV1% pred. ≥ 80%) 9.0 4.6 4.7 4.0
% Grade 2 (50 ≤ FEV1% pred. < 80) 42.3 34.4 24.5 76.0
% Grade 3 (30 ≤ FEV1% pred. < 50) 38.1 42.8 50.9 8.0
% Grade 4 (FEV1% pred. < 30) 10.5 18.3 19.8 12.0
Education <.001b .86b
% Basic school education 57.0 32.1 33.0 28.0
% Secondary school education 26.0 43.5 42.5 48.0
% Higher school education 17.0 24.4 24.5 24.0
Smoking status <.001b .25b
% Never smokers 5.4 23.7 20.8 36.0
% Former smokers 69.2 75.6 78.3 64.0
% Smokers 25.4 0.7 0.9 0.0
BMI (kg/m2) 26.8 (5.3) 24.7 (4.0) 24.6 (4.1) 24.8 (3.6) <.001a .85a
% Normal weight (18.5≤ BMI < 25) 35.7 52.7 52.8 52.0 <.001b .64b
% Overweight (25≤ BMI < 30) 37.1 33.6 32.1 40.0
% Obese (BMI≥ 30) 23.7 9.9 10.4 8.0
% Underweight (BMI < 18.5) 3.5 3.8 4.7 0.0
Comorbidities
Count 3.9 (2.6) 3.1 (2.5) 3.0 (2.5) 3.4 (2.3) <.001c .30c
% Liver cirrhosis 1.3 1.5 1.9 0.0 .68b .49b
% Hepatitis 5.4 6.9 8.5 0.0 .48b .13b
Data are mean (standard deviation) or percentage (%)
A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B = COPD patients with AATD, B1 = COPD patients with AATD and augmentation therapy (AT),
B2 = COPD patients with AATD but without AT
ap-value based on t-test, bp-value based on Chi2-test, cWilcoxon signed rank test
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Table 2 Unadjusted healthcare utilization, costs and health-related quality of life
Healthcare utilization Subgroups
A B B1 B2
(n = 2049) (n = 131) (n = 106) (n = 25)
Outpatient services (3 months)
General practitioner
% User 76 66 64 76
Number of visits 1.9 (2.3) 3.8 (4.8) 4.1 (5.0) 2.7 (3.7)
Specialists
% User 94 96 96 96
Number of visits 4.4 (4.4) 8.9 (7.4) 9.6 (7.0) 5.9 (8.5)
Ambulant hospital visits
%User 16 18 18 16
Number of visits 0.3 (1.5) 0.7 (3.0) 0.8 (3.3) 0.2 (0.4)
Inpatient services (12 months)
% User 39 24 24 24
Number of visits 0.6 (1.1) 0.3 (0.8) 0.4 (0.9) 0.3 (0.5)
Duration of stay 5.8 (14.1) 2.3 (5.8) 2.2 (5.7) 2.7 (6.3)
Rehabilitation (12 months)
Ambulant
% User 2 4 3 8
Number of visits 0.5 (4.2) 0.6 (3.1) 0.5 (2.8) 1.16 (4.0)
Stationary
% User 14 21 22 16
Duration of stay 3.3 (8.8) 5.2 (10.9) 5.4 (10.6) 5.0 (12.3)
Physiotherapist (12 months)
%User 35 52 51 56
Number of visits 7.1 (18.5) 15.2 (23.6) 15.2 (24.1) 14.9 (22.1)
Medication (7 days)
Number of prescribed medications (without AT) 6.1 (3.2) 4.7 (2.7) 4.7 (2.6) 4.4 (3.1)
Direct costs (12 months)
Outpatient costs 938 (834) 2160 (1547) 2423 (1559) 1044 (857)
Inpatient costs 3441 (8302) 1341 (3394) 1285 (3337) 1579 (3687)
Rehabilitation 433 (1086) 674 (1327) 675 (1293) 666 (1487)
Physiotherapist 118 (307) 252 (393) 253 (400) 247 (368)
Medication costs 2533 (3327) 1961 (1076) 2056 (1080) 1558 (976)
Medication costs including AT 2533 (3327) 60427 (28718) 74311 (1080) 1558 (976)
Total direct costs 7446 (9836) 6374 (4535) 6675 (4202) 5096 (5655)
Total direct costs incl. AT 7446 (9836) 64840 (29467) 78930 (4202) 5096 (5655)
Indirect costs (participants < 65 years) Subgroups
A B B1 B2
(n = 897) (n = 82) (n = 69) (n = 13)
Work absenteeism (12 months)
% retired 47 35 37 23
% employed 38 55 54 62
% thereof with sick days (12 months) 73 67 59 100
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AATD patients receiving ATcompared to AATD patients
not receiving AT visited a general practitioner or specialist
about two times more often and had a higher rate of pre-
mature retirement (37% vs. 23%). It has to be noted that
the number of outpatient visits of AT receiving AATD pa-
tients did most likely include visits for AT application as in-
formation on the purpose of visits was missing.
Association of AATD and AT with direct and indirect costs
All cost estimates considered in the following analyses ex-
clude the costs of AT therapy; thus estimated mean an-
nual costs of approximately €72,000 [21] have to be added
in patients receiving AT.
Table 3 shows the major results of regression models for
costs. Adjusted for possible confounders, there were no sig-
nificant associations of AATD (with or without AT) with
total direct costs. However, AATD patients with AT showed
significantly higher annual outpatient costs (factor 2.7, p <
0.001) compared to patients without AATD. Conversely,
AT-receiving patients had lower inpatient costs (−35%, p =
0.02). Medication costs, excluding AT costs, were decreased
by 10% (p = 0.11) and 28% (p = 0.01) in AATD patients with
and without AT, respectively. As stated before, these results
were not adjusted for the reason of consultation. Therefore,
the number of outpatient visits in AATD patients with AT
may include a number of visits that were exclusively due to
AT administration. There were no significant associations
of AATD with indirect cost neither for the human capital
nor the friction cost approach. Complete regression results
are shown in Additional file 2.
Adjusted mean annual direct and indirect costs are
shown in Table 4. Total annual direct costs due to health-
care, were highest in COPD patients without AATD (€7460
[€7026 – €7924]) and lowest in patients with AATD but
without AT €6099 ([€4288 – €8256]). AATD patients with
AT had mean annual direct cost of €7117 ([€6029 –
€8392]). The categories of direct costs, in relation to the
total amount of direct costs in the three subsamples, are il-
lustrated in Fig. 2. Inpatient costs contributed most to the
total healthcare costs in COPD patients without AATD
(€3586 [€3201 – €4010]) and AATD patients without AT
(€2338 [€561 – €5288]). Most cost driving category in
AATD patients with AT was outpatient costs (€2570
[€2256 – €2866]).
Comparison of HRQL in the three subgroups
There were no significant differences regarding HRQL
between the groups. In particular, having AATD with or
without AT was not associated with differences in CAT,
SGRQ, EQ-5D-3 L utility or EQ-5D VAS compared to
patients without AATD. Results from regression analyses
are shown in Table 5; detailed regression results can be
found in Additional file 3. Adjusted mean HRQL scores
are provided in Fig. 3.
Result of sensitivity analysis
Using FEV1 in terms of the exact %predicted instead of
GOLD grades 1 to 4 for adjustment in regression models
did not affect the association between patient groups and
costs or HRQL. Thus there is no indication of residual
Table 2 Unadjusted healthcare utilization, costs and health-related quality of life (Continued)
Number of sick days 30.8 (50.9) 24.8 (46.7) 24.2 (50.1) 27.6 (28.0)
Indirect costs (12 months)
Costs due to sick days (HC) 5452 (9015) 4395 (8278) 4287 (8882) 4895 (4965)
Costs due to sick days (FC) 2541 (2585) 2161 (2392) 1935 (2374) 3208 (2338)
Premature retirement (HC) 17508 (18543) 13129 (17859) 13989 (18123) 8568 (16280)
Total indirect costs (HC) 19514 (17615) 15541 (17231) 16288 (17595) 11580 (15155)
Total indirect costs (FC) 935 (1989) 1186 (2069) 1038 (1982) 1974 (2413)
Health-related Quality of Life Subgroups
A B B1 B2
(n = 2049) (n = 131) (n = 106) (n = 25)
SGRQ 44.0 (20.0) 44.8 (17.2) 46.6 (16.4) 37.5 (20.2)
CAT 18.3 (7.4) 18.6 (6.7) 18.9 (6.6) 17.2 (7.3)
EQ-5D-3 L utility 81.5 (20.7) 83.2 (19.1) 83.0 (19.1) 83.9 (19.4)
EQ-5D VAS 56.2 (19.4) 56.4 (19.0) 54.4 (18.8) 63.6 (18.75)
Data are mean (standard deviation) or percentage (%)
A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B = COPD patients with AATD, B1 = COPD patients with augmentation therapy (AT), B2 = COPD
patients with AATD but without AT, HC = human capital approach, FC = friction costs approach
Number of visits is including all participants, also those who have 0 visits
Total direct and indirect costs differ from the sum score calculated from the single categories due to differences in n between the single categories. EQ-5D-3 L
utility is displayed after multiplication with 100
Total direct costs do not include AT costs of approximately €72,000
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confounding by using the GOLD grades 1 to 4 instead of
the continuous variable FEV1%pred. Details are shown in
Additional files 4 and 5.
Discussion
This study compared costs and HRQL between COPD pa-
tients with AATD (with or without AT) and COPD pa-
tients without this deficiency. Costs of AT therapy (about
€72,000 per year [21]) were excluded in order to identify
the healthcare costs as a function of the patient group.
AATD patients, both with and without AT, tended to have
lower total costs compared to COPD patients without
AATD, but these differences did not reach statistical sig-
nificance. Accordingly, most of the single cost categories
also did not show significant differences. However, ad-
justed mean medication costs were significantly lower in
both AATD patient groups compared to COPD patients
without AATD. Outpatient costs were considerably in-
creased in AATD patients with AT, while inpatient costs
were lower. There were no differences found between the
groups regarding indirect costs or HRQL.
A recent study by Greulich et al. [33] that examined
German claims data of about 2.8 million insurants over a
time period of four years conducted an age- and gender-
matched (1:10) comparison between 5,900 COPD patients
without AATD and 590 COPD patients with AATD.
AATD patients had more outpatient consultations and a
higher hospitalization rate compared to COPD patients
without AATD [33]. These results were not adjusted for
disease severity or stratified by AT which might explain
the, compared to our results, opposite finding regarding
the hospitalization rate of AATD patients. With respect to
the higher frequency of outpatient service consultation in
AATD patients, Greulich et al., like us, point out that this
is at least in part explainable by AT application [33].
Another study by Zacherle et al. using US claims
data also found significantly more inpatient visits in
AATD patients compared to COPD patients without
Table 3 Results of regression models: Association of AATD and AT with annual direct and indirect costs
Direct costs Indirect costs
Costs Total direct costs Outpatient costs Inpatient costs Medication costs Other costs HC FC
Group A Ref. Ref. Ref. Ref. Ref. Ref. Ref.
B1 0.95 (0.80 – 1.12) 2.73 (2.35 – 3.17) 0.65 (0.45 – 0.94) 0.90 (0.79 – 1.03) 1.14 (0.81 – 1.61) 1.05 (0.79 – 1.39) 0.94 (0.66 – 1.35)
B2 0.80 (0.57 – 1.13) 1.13 (0.84 – 1.51) 0.79 (0.39 – 1.63) 0.72 (0.56 – 0.93) 1.23 (0.65 – 2.34) 0.67 (0.38 – 1.18) 1.18 (0.67 – 2.08)
A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD
but without AT
Indirect costs only include patients < 65 years of age
Significant estimates on a level of p < .05 are printed bold
Other costs include Physiotherapist and Rehabilitation costs
HC Human capital approach, FC Friction costs approach
Total direct costs and medication costs do not include AT costs of approximately €72,000
Table 4 Adjusted annual direct and indirect costs
Adjusted mean annual costs (€)
Direct costs Total Outpatient costs Inpatient costs Medication costs Other costs
% zero costs 0% 0% 62% 0% 56%
Group
A 7460 [7026 – 7924] 937 [902 – 973] 3586 [3201 – 4010] 2522 [2381 – 2663] 566 [513 – 628]
B1 7117 [6029 – 8392] 2570 [2256 – 2866] 1715 [740 – 3076] 2144 [1903 – 2409] 777 [529 – 1049]
B2 6099 [4288 – 8256] 1061 [763 – 1414] 2338 [561 – 5288] 1805 [1388 – 2261] 876 [319 – 1659]
Adjusted mean annual costs (€)
Indirect costs Human capital approach Friction costs approach
% zero costs 26% 72%
Group
A 19,583 [18,451 – 20,803] 981 [839 – 1138]
B1 18,813 [13,632 – 24,716] 1276 [608 – 2181]
B2 16,171 [6194 – 28,316] 1866 [633 – 3764]
A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but
without AT
Significant estimates on a level of p < 0.05 are printed bold. Indirect costs only include participants < 65 years of age
Totals direct costs and medication costs do not include AT costs of approximately €72,000
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AATD (58% vs. 19.5%) leading to an increase by
$US27,674 in total healthcare costs per patient [34].
However, this study included the AT costs of AT-
receiving AATD patients (13% in the sample) and was
not adjusted for differences in COPD severity. In an-
other US survey Mullins et al. performed a cost ana-
lysis on AATD patients in 2003 and identified mean
costs per year for hospitalization, outpatient services
and prescription of drugs (other than AT) of
$US4,497, $US2,299, and $US6,456, respectively [35].
These costs are higher than the costs estimated for
the COSYCONET dataset. The differences could be
due to a lack of adjustment for case severity and to
national cost differences. In COSYCONET, indirect
costs did not show significant differences between
COPD patients with and without AATD. However,
Zacherle et al. found COPD patients without AATD
to receive disability benefits twice as often as AATD
patients (40.1% vs. 20.3%, p < 0.001) [34]. To the
knowledge of the authors, the present study is the
first one comparing indirect costs in COPD patients
with and without AATD in a comprehensive manner.
After stratification of AATD patients for AT, some
differences appeared regarding single direct cost fac-
tors. Patients receiving AT showed considerably in-
creased outpatient but decreased inpatient costs
Fig. 2 Displays the four direct cost categories in relation to the total amount of direct costs. Patients with Alpha-1-antitrypsin deficiency (AATD)
and augmentation therapy (AT) have lower inpatient but also higher outpatient costs, compared to the two other subgroups. Therefore, no sig-
nificant differences could be detected between the three groups. However, AATD patients - especially non AT receiving AATD patients - tended
to have lower direct costs
Table 5 Results of regression models: Regression coefficients of AATD patients with and without AT
Regression coefficients
HRQL SGRQ CAT EQ-5D-3 L utility EQ-5D VAS
Group A Ref. Ref. Ref. Ref.
B1 2.68 (−0.82 – 6.19) 0.66 (−0.73 – 2.04) −0.55 (−4.45 – 3.35) −1.58 (−5.23 – 2.07)
B2 −0.64 (−7.53 – 6.24) 0.60 (−2.09 – 3.31) −1.67 (−9.34 – 6.00) 2.14 (−5.01 – 9.30)
Group A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), Group B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients
with AATD but without augmentation therapy
EQ-5D-3 L utility was multiplied by 100
Significant estimates on a level of p < 0.05 are printed bold
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compared to COPD patients and AATD patients not
receiving AT. Other studies relevant for inpatient or
outpatient costs examined exacerbation rates or FEV1
and showed inconsistent or not significant results
[15]. The increase of outpatient costs in patients re-
ceiving AT in our study is at least partially explain-
able by the AT itself which is usually administered by
a weekly intravenous infusion in the outpatient set-
ting. As we did not have information on the reason
for individual physician visits, these costs could not
be specified in our analysis. Conversely, the decreased
inpatient and medication costs might be a beneficial
side-effect of the more frequent outpatient visits asso-
ciated with the AT. The more frequent visits at out-
patient services might lead to a better adherence to
self-management plans and compliance to medication
plans. Furthermore, they might facilitate the early de-
tection of changes in needs and clinical picture of the
patients and therefore prevent hospitalisation. This ef-
fect may also, at least partially, explain the overall al-
though not significant lower costs in AATD patients.
Our finding that HRQL did not differ between
COPD patients with and without AATD is in line
with former research by Manca et al. who did not
find HRQL differences between AATD patients and
COPD patients without AATD, regarding CAT, EQ-
5D-3 L and EQ-5D VAS [36]. HRQL also did not dif-
fer between AATD patients with and without AT.
Similar results were found in a randomized, placebo-
controlled trial by Chapman et al. [37] in which
SGRQ values did not differ significantly (44.3 vs. 42.4,
p = 0.91) between AATD patients with and without
AT. The results presented in the review by Gøtzsche
et al. also suggest no clinically relevant differences in
HRQL (41).
When considering the cost reductions due to less
usage of inpatient services and prescribed medication
in AT-receiving AATD patients, it has to be kept in
mind that these patients cause very high total annual
costs of about €72,000 due to augmentation therapy.
Our study shows that this amounts for about 91% of
the total direct costs in AATD patients receiving AT.
In our opinion, the finding that HRQL did not differ
between AATD patients with AT and COPD patients
without AATD does not allow conclusions about the
effect of AT on HRQL. In particular AATD patients
not receiving AT could not serve as a control group
for AT-receiving AATD patients, as we did not have
access to the detailed information that had led to
the prescription of AT. The AATD patients without
AT were older and had less severe COPD compared
to AATD patients with AT. This could be partly
Fig. 3 Displays the four HRQL scales in comparison between the three subgroups. No differences could be detected. AATD = Alpha-1-antitrypsin
deficiency, AAT = augmentation therapy
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explained by therapeutic guidelines, which indicate
to prescribe AT only in severe cases with minimal
smoking history [38]. Nevertheless, our results
underline how important information on treatment
effects of AT on HRQL of AATD patients is both
medically and economically. Thus clarification of the
(cost-) effectiveness of AT should have high priority
in AATD research.
There have been several efforts to estimate the cost
effectiveness of AT, however with inconsistent results
[39, 40]. From the perspectives of both health econom-
ics and morbidity profiling it is of interest whether the
costs of standard COPD therapy depend on the pres-
ence of AATD and the use of AT. We provide such
data regarding single direct and indirect cost factors,
and the results can be used as more precise estimators
of yearly costs in the three patient groups.
Recently there has been new supporting evidence
for the effectiveness of AT in AATD therapy by a
randomized clinical trial [41]. However, our finding of
indifferent costs also raises the question how a poten-
tially intensified but standard COPD therapy com-
pares with additional AT and which long-term health
and cost benefits might be associated with these op-
tions. Due to AATD patients often being excluded
from pharmacologic trials on COPD therapy, there is
actually a lack of evidence on the impact of standard
therapy on this patient group.
The strength of the study is based on a sample
size that enabled us to include sufficient numbers of
patients in all three patient groups, with respect to
the rarity of AATD. Furthermore, the COSYCONET
COPD cohort acquired detailed information to ana-
lyse direct and indirect costs, as well as generic and
disease-specific HRQL. There are, however, also limi-
tations. The analysis of healthcare utilisation relied
on self-reported questionnaires, with the risk of re-
call bias. However, there were no hints for differen-
tial biases between groups. Some healthcare services
such as nursing, medical aids and appliances were
not considered in the cost calculations. Finally, in
this cross-sectional study only statistical associations
could be explored. Despite the limitations it is rea-
sonable to assume that the estimates derived from
the baseline visit of COSYCONET give a realistic
picture of direct and indirect costs as well as of the
HRQL in COPD with and without AATD and AT.
Conclusion
If AT costs were excluded, AATD patients tended to show
lower, but not significant, overall costs and similar HRQL
compared to COPD patients without AATD. AT was not
associated with lower costs or higher HRQL from a cross-
sectional perspective.
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